FY2022 Earnings Estimate for Juno Therapeutics Inc (JUNO) Issued By Wedbush

Juno Therapeutics Inc (NASDAQ:JUNO) – Equities research analysts at Wedbush issued their FY2022 earnings estimates for shares of Juno Therapeutics in a report issued on Wednesday. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will post earnings of ($0.71) per share for the year. Wedbush currently has a “Neutral” rating on the stock.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the previous year, the business earned ($0.57) earnings per share. The firm’s revenue was up 115.4% compared to the same quarter last year.

A number of other equities research analysts have also issued reports on the stock. Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a report on Wednesday. Citigroup lowered shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Wells Fargo & Co restated a “market perform” rating and set a $63.00 price target (up previously from $54.00) on shares of Juno Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Juno Therapeutics in a report on Thursday, January 11th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $47.26.

Juno Therapeutics (NASDAQ:JUNO) traded down $3.56 during mid-day trading on Friday, hitting $67.81. 5,220,193 shares of the stock were exchanged, compared to its average volume of 3,350,000. Juno Therapeutics has a twelve month low of $19.07 and a twelve month high of $74.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The firm has a market capitalization of $7,740.00, a price-to-earnings ratio of -20.00 and a beta of 2.32.

Institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. increased its stake in Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the period. The Manufacturers Life Insurance Company increased its stake in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the period. State of Alaska Department of Revenue acquired a new position in Juno Therapeutics in the 4th quarter valued at approximately $173,000. Finally, QS Investors LLC bought a new stake in Juno Therapeutics in the second quarter worth approximately $135,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 270,250 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Robert Azelby sold 1,816 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the transaction, the executive vice president now owns 70,832 shares in the company, valued at approximately $3,184,606.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 365,337 shares of company stock worth $17,540,499. Company insiders own 15.08% of the company’s stock.

WARNING: “FY2022 Earnings Estimate for Juno Therapeutics Inc (JUNO) Issued By Wedbush” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2018/01/19/fy2022-earnings-estimate-for-juno-therapeutics-inc-juno-issued-by-wedbush.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply